Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Fiscus, Susan, et al. Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy In Children (pactg 338). BioMed Central Ltd, 2007. https://doi.org/10.17615/pabd-xs44APA
Fiscus, S., Kovacs, A., Petch, L., Hu, C., Wiznia, A., Mofenson, L., Yogev, R., Mc Intosh, K., Pelton, S., Napravnik, S., Stanley, K., & Nachman, S. (2007). Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). BioMed Central Ltd. https://doi.org/10.17615/pabd-xs44Chicago
Fiscus, Susan, Andrea Kovacs, Leslie A Petch, Chengcheng Hu, Andrew A Wiznia, Lynne M Mofenson, Ram Yogev et al. 2007. Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy In Children (pactg 338). BioMed Central Ltd. https://doi.org/10.17615/pabd-xs44- Creator
-
Fiscus, Susan
- Affiliation: School of Medicine, UNC Center for AIDS Research, Department of Microbiology and Immunology
-
Kovacs, Andrea
- Other Affiliation: Maternal, Child and Adolescent Program, University of Southern California Medical Center, Los Angeles, CA, USA
-
Petch, Leslie A
- Affiliation: School of Medicine, UNC Center for AIDS Research
-
Hu, Chengcheng
- Other Affiliation: Center for Biostatistics in AIDS Research and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
-
Wiznia, Andrew A
- Other Affiliation: Department of Pediatrics, Jacobi Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA
-
Mofenson, Lynne M
- Other Affiliation: Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA
-
Yogev, Ram
- Other Affiliation: Division of Infectious Diseases, Children's Memorial Hospital and Northwestern University School of Medicine, Chicago, IL, USA
-
McIntosh, Kenneth
- Other Affiliation: Division of Infectious Diseases, Children's Hospital and Harvard Medical School, Boston, MA, USA
-
Pelton, Stephen I
- Other Affiliation: Department of Pediatrics, Boston Medical Center, Boston, MA, USA
-
Napravnik, Sonia
- Affiliation: School of Medicine, UNC Center for AIDS Research
-
Stanley, Kenneth
- Other Affiliation: Center for Biostatistics in AIDS Research and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
-
Nachman, Sharon A
- Other Affiliation: Department of Pediatrics, SUNY Health Science Center at Stony Brook, Stony Brook, NY, USA
- Abstract
- Abstract Background The association between baseline drug resistance mutations and subsequent increase in viral failure has not been established for HIV-infected children. We evaluated drug resistance mutations at 39 codon sites (21 protease inhibitor (PI) resistant codons and 18 nucleoside reverse transcriptase inhibitor (NRTI) resistant codons) for 92 clinically stable NRTI-experienced, PI-naive HIV-infected children 2 to 17 years of age who were initiating new therapy with ritonavir plus zidovudine (ZDV) and lamivudine or plus stavudine. The association between baseline drug resistance mutations and subsequent viral failure after 12 and 24 weeks of highly active antiretroviral therapy (HAART) was studied. Results There were few primary PI associated mutations in this PI-naïve population, but 84% had NRTI mutations – codons 215 (66%), 41 (42%), 67 (37%), 210 (33%) and 70 (32%). None of the specific baseline drug resistance mutations were associated with a higher rate of virologic failure after 12 or 24 weeks of HAART. Median week 12 viral load decreased as the total number of NRTI mutations at baseline increased (P = 0.006). Specifically, a higher level of baseline ZDV resistance mutation was associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART regimen (P = 0.017). Conclusion No increase was seen in the rate of viral failure after HAART associated with the presence of resistance mutations at baseline. This paradoxical result may be due to adherence, replicative capacity, or ZDV hypersusceptibility to the new regimen.
- Date of publication
- February 6, 2007
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Rights holder
- Susan A Fiscus et al.; licensee BioMed Central Ltd.
- License
- Journal title
- AIDS Research and Therapy
- Journal volume
- 4
- Journal issue
- 1
- Page start
- 2
- Language
- English
- Is the article or chapter peer-reviewed?
- Yes
- ISSN
- 1742-6405
- Bibliographic citation
- AIDS Research and Therapy. 2007 Feb 06;4(1):2
- Publisher
- BioMed Central Ltd
- Access right
- Open Access
- Date uploaded
- September 5, 2012
Relations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
1742-6405-4-2.pdf | 2019-05-06 | Public | Download | |
1742-6405-4-2.xml | 2019-05-06 | Public | Download |